Chronic refractory cough treatment sales will grow through 2036, led by corticosteroids at 27.4% of the drug class segment in 2026. The market was valued at USD 10.41 billion in 2025 and is expected to be worth USD 19.56 billion by 2036, creating an incremental opportunity of USD 8.54 billion.